FDA Approval Alert: The Need-to-Know | Telisotuzumab Vedotin in c-MET+ NSCLC

In May 2025, the FDA granted accelerated approval to telisotuzumab vedotin-tllv as a treatment for adults with locally advanced or metastatic nonsquamous non–small cell lung cancer and high c-MET protein expression previously managed with systemic therapy.

With this decision, telisotuzumab vedotin is the first and only available therapy for this NSCLC subtype.
Telisotuzumab Vedotin Earns FDA Accelerated Approval in c-MET+ NSCLC
Article
May 14, 2025 6:10 PM
Data from the phase 2 LUMINOSITY study support the FDA approval of telisotuzumab vedotin in this non–small cell lung cancer population.